Please ensure Javascript is enabled for purposes of website accessibility

Why AstraZeneca Briefly Lost $11.3 Billion in Market Capitalization

By George Budwell - Sep 9, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A large phase 3 trial for the drugmaker's COVID-19 vaccine has been put on hold.

What happened

Global biopharma giant AstraZeneca (AZN 1.01%) briefly lost approximately $11.3 billion in market capitalization after the closing bell Tuesday afternoon. The drugmaker's shares sank by as much as 8% in after-hours trading yesterday in response to the news that the large phase 3 trial of its COVID-19 vaccine, which is being co-developed with the University of Oxford, has been put on hold due to a potential adverse reaction in a participant.

AstraZeneca's stock has since rebounded to a large degree, thanks to reassuring comments from British health minister Matt Hancock about the routine nature of this safety review. However, the company's stock is still off by around 2.36% in pre-market action Wednesday morning. 

Stacks of hundred dollar bills.

Image source: Getty Images.

So what

AstraZeneca is in a close race with Pfizer and Moderna to be among the first Western-based companies to successfully develop a COVID-19 vaccine. In fact, there have been multiple rumors swirling of late that AstraZeneca's vaccine candidate may be approved ahead of the U.S. presidential election on a conditional, accelerated basis, although the company has openly pledged not to rush the vaccine's regulatory review.

This pause in the vaccine's pivotal trial, though, could give an important competitive edge to Pfizer and Moderna, depending on how long it lasts. AstraZeneca's shareholders were clearly unsettled by this possibility, which is understandable given that the first wave of commercial-stage COVID-19 vaccines are all expected to be high-value products for their manufacturers.  

Now what

AstraZeneca plans to complete a safety review of the incident as soon as possible in order to get this key trial back on track. That said, this overtly negative reaction among investors to this trial halt is arguably unwarranted. AstraZeneca has one of the best product portfolios, clinical pipelines, and shareholder rewards programs in the industry. Moreover, this single vaccine is not a make-or-break product for this top pharma company -- not by a long shot. Bargain hunters, in turn, may want to buy AstraZeneca's shares on any weakness stemming from this news. 

 

George Budwell owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.17 (1.01%) $0.67
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.15 (1.17%) $0.57
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$146.10 (-2.60%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.